Mercury Biopharmaceutical Corporation

6932 · TWO · Healthcare / Drug Manufacturers - Specialty & Generic

5.21TWD-0.01 (-0.19%)

Price History

Full chart

Market Stats

Previous Close5.22

Open5.22

Day Range4.97 – 5.22

52-Week Range4.71 – 12.20

Volume159.12K

Market Cap2.61B

P/E (TTM)0.00

Forward P/E0.00

EPS-0.12

Dividend Yield0.00%

Beta-1.11

50-Day Avg5.71

200-Day Avg7.20

About

Merdury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan. The company develops StackDose platform, a drug development technology platform that integrates drug formulation, 3D powder printing, and hardware and software technologies to create drug-specific 3D printing production equipment, which can be used as a foundation for pharmaceutical companies to provide hosted services and in-house product development. It also offers formulation design and 3D pharmaceutical processing services. Merdury Biopharmaceutical Corporation was founded in 2019 and is headquartered in New Taipei City, Taiwan.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. Yaoren Liang
Employees0
HeadquartersNo. 653, Bannan Rd., New Taipei City, Taiwan, 235030, Taiwan
Websitehttps://merdury.com

Leadership

Mr. Yaoren LiangGM & Director
Chun Chun ZhangVP of Administration & Accounting Supervisor
Mr. Ruixing ChenLegal Director & Director
Mr. Nanxiong ZhangChief Marketing Officer & Director
Chaoyi ChenChief Research & Development Officer

Financials

Income Statement

Currency: TWD	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	-	0	2.68M	1.03M	4.96M	0
Growth (%)	-	-	-	-61.46%	+380.45%	-100.00%
Cost of Revenue	-	0	1.51M	441.00K	779.00K	0
Gross Profit	-	0	1.17M	592.00K	4.18M	0
Gross Margin	-	-	43.73%	57.31%	84.30%	-
Operating Expense	-	5.30M	32.02M	43.70M	58.23M	68.55M
Operating Income	-210.00K	-5.30M	-30.85M	-43.10M	-54.04M	-68.55M
Operating Margin	-	-	-1151.12%	-4172.80%	-1088.90%	-
EBITDA	-210.00K	-4.33M	-28.10M	-39.03M	-42.27M	-54.64M
EBITDA Margin	-	-	-1048.62%	-3778.70%	-851.78%	-
Net Income	-210.00K	-5.31M	-31.25M	-43.82M	-50.57M	-67.23M
Net Income Margin	-	-	-1166.04%	-4241.63%	-1018.90%	-
R&D	-	2.82M	15.41M	21.37M	32.66M	44.18M
R&D as % of Total Revenue	-	-	575.00%	2068.54%	657.97%	-
Interest Expense	-	11.00K	400.00K	711.00K	801.00K	898.00K
Interest Expense % of Total Revenue	-	-	14.93%	68.83%	16.14%	-

Balance Sheet

Currency: TWD	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	157.00K	97.00K	13.38M	229.93M	438.07M	353.20M	278.39M
Total Liabilities	156.00K	306.00K	2.92M	49.60M	49.72M	62.93M	58.72M
Total Equity	1.00K	-209.00K	10.46M	180.33M	388.35M	290.27M	219.67M
Cash	153.00K	86.00K	2.56M	31.94M	44.29M	68.01M	53.17M
Total Debt	150.00K	300.00K	2.01M	43.42M	42.35M	-	-
Net Debt	-3.00K	214.00K	-550.00K	11.49M	-1.95M	-	-

Cash Flow

Currency: TWD	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-197.00K	-217.00K	-4.78M	-25.84M	-42.15M	-34.71M	-50.84M
Financing Cash Flow	350.00K	150.00K	15.28M	240.61M	248.93M	-	-
Capital Expenditure	0	0	7.51M	68.65M	13.57M	11.10M	7.30M
Free Cash Flow	-197.00K	-217.00K	-12.29M	-94.50M	-55.72M	-45.81M	-58.14M
FCF to OCF	100.00%	100.00%	257.04%	365.66%	132.20%	131.98%	114.35%

Key Statistics & Ratios

Market Cap2.61B

Enterprise Value2.48B

Trailing P/E0.00

Forward P/E0.00

Price / Sales13553.62

Price / Book12.82

EPS-0.12

Book Value0.469

Revenue (TTM)246.00K

Gross Profit (TTM)208.00K

EBITDA-43.24M

Profit Margin0.00%

Operating Margin0.00%

Return on Equity-22.78%

Return on Assets-11.40%

Shares Outstanding427.65M

Shares Float202.16M

Beta-1.11

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%